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Conclusion: Our study shows that miR-625-3p induces oxaliplatin resistance
by abrogating MAP2K6-p38 regulated apoptosis and cell cycle control
networks, and corroborates the predictive power of miR-625-3p. This has
signiﬁcant clinical potential as the expression level of miR-625-3p, possibly
combined with the expression level of MAP2K6, has the potential to serve
as a predictive biomarker. Since ~20% of metastatic CRC patients have high
miR-625-3p expression, the number of patients potentially beneﬁting from the
use of miR-625-3p/MAP2K6 is substantial.
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Background: Hedgehog (Hh) pathway is essential for tissue development
and stemness, and when deregulated leads to tumorigenesis. Although many
Hedgehog-driven human cancers involve upstream pathway activation (i.e.
either loss-of-function of the receptor Ptch1 or gain-of-function mutations of
the transmembrane transducer Smo), Smo-independent hyperactivation of
the downstream Gli transcription factor is responsible for the development of
several tumors and resistance to therapy. This raises the need to identify novel
Gli1 inhibitors, a challenging issue mostly due to the lack of information on the
structural requirements of Gli1/DNA interaction.
Material and Methods: Molecular characterization of Gli1/DNA binding was
performed by a mix of computational and experimental structure-based in
vitro studies. Molecular dynamics simulations were carried out to identify the
residues in Gli1 zinc-ﬁnger involved in DNA binding. The data obtained were
then used to set up the docking-based virtual screening of a natural products
library available in house, with the aim to discover pharmacological agents able
to interfere with Gli1/DNA interaction. The molecules identiﬁed as potential
Gli1 inhibitors were investigated for their functional activity through a Gli-
dependent luciferase reporter screening assay. The most active was tested for
its effectiveness to counteract Hh-dependent tumor growth by medulloblastoma
and basal cell carcinoma allograft model from Ptch+/− mice and ortothopic
medulloblastoma xenograft.
Results:We identiﬁed a small molecule, Glabrescione B (GlaB), an isoﬂavone
naturally found in the seeds of Derris glabrescens (Leguminosae), able to
impair Gli1/DNA binding as revealed by Chip and EMSA assays. In agreement
with these molecular results, GlaB revealed great antitumor efﬁcacy. Indeed,
we observed that GlaB strongly inhibited the growth of Hedgehog-dependent
tumor cells in vitro and in vivo as well as the self-renewal ability and
clonogenicity of tumor-derived stem cells.
Conclusions: Our study highlighted the relevance of structural details of
Gli1/DNA interaction as a promising tool to discover small molecules able
to inhibit Hh pathway by directly targeting Gli1. Here we identiﬁed GlaB as
a potent and speciﬁc Gli1 inhibitor able to interfere with Gli1/DNA binding,
resulting in the inhibition of Hh-dependent tumor cells and cancer stem cells
growth, thus becoming a proﬁtable pre-clinical candidate.
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Introduction: An abnormal number of chromosomes, or ‘aneuploidy’, is a
common feature of solid human tumors and a predictor of poor prognosis
in breast, lung, brain and colorectal cancer. Aneuploidy is caused by
malfunctioning of the Spindle Assembly Checkpoint (SAC), a surveillance
mechanism that ensures the ﬁdelity of chromosome segregation. The protein
kinase TTK (commonly referred to as Mps1) is a component of the SAC.
Inhibition of TTK gene expression by RNA interference and inhibition of
TTK kinase activity by small molecule kinase inhibitors causes chromosome
missegregation and cancer cell death.
Material and Method: A novel class of compounds was identiﬁed that
potently inhibits TTK enzyme activity and cancer cell line proliferation [1]. Its
binding mode and that of reference inhibitors was characterized by protein
crystallography. Binding kinetics and target residence time were determined
by surface plasmon resonance. Anti-proliferative activity was measured on a
broad panel of cancer cell lines [2,3].
Results and Discussion: The clinical candidate, NTRC 0066-0, inhibits TTK
with subnanomolar potency (IC50) in a kinase enzyme assay and is more
than 200 times selective over 276 kinases examined, including mitotic and cell
cycle dependent kinases (CDKs). X-ray structures of the TTK kinase domain in
complex with NTRC 0066-0 and analogs indicate that this class of compounds
induces a large conformational shift in the glycine-rich loop, invoking an
inactive kinase conformation. In surface plasmon resonance experiments,
NTRC 0066-0 exhibited slow dissociation kinetics, resulting in a long target
residence time. Parallel surface plasmon resonance experiments conﬁrmed
the exquisite selectivity of NTRC 0066-0 for TTK over Aurora and Polo-like
kinases. NTRC 0066-0 inhibited the proliferation of a wide variety of human
cancer cell lines in the same potency range as marketed cytotoxic agents. The
crystal structure, binding kinetics and cellular potency of NTRC 0066-0 were
compared to that of other TTK inhibitors such as Mps1-IN-2, AZD-3146, Mps-
BAY2b, Bay 1161909 as well as analogs from the NTRC 0066-0 series. This
suggests that the unique binding mode of NTRC 0066-0 results in long target
residence time which contributes to its strong anti-tumor activity. In subsequent
mouse xenograft models of human cancer cell lines, NTRC 0066-0 inhibited
tumor growth as a single agent after oral administration at 20mg per kg.
Conclusions: NTRC 0066-0 is a novel TTK inhibitor with outstanding in vitro
properties and potent anti-tumor activity in mouse xenograft models. Our data
suggest that long target residence time corresponds with potent cellular activity
for TTK inhibitors.
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Background: Pancreatic cancer is the 4th most aggressive cancer in the
western world with less than 34% of patients surviving past 5 years. Lack
of speciﬁc symptoms results in delayed diagnosis. Theranostics are new
platforms, which offer simultaneous diagnosis and therapy resulting in a
decrease in treatment time. Here treatments are conjugated onto diagnostics
by stimuli responsive binding allowing for controlled drug release resulting in
a rapid and localised clinical effect. Hybrid nanoparticles are composed of
an iron oxide core surrounded by a rigid gold shell. These particles undergo
manipulation due to inherent magnetism of the core whilst laser irradiation of
their gold shell results in localised heating due to surface plasmon resonance.
Hence, they can be utlilised as diagnostics using MRI and laser irradiation can
be used as a trigger for drug release.
Methods: Proof of concept studies have been carried out using a novel
bisnaphthalamido (BNIP) based drug series. BNIPs are a series of novel
compounds, which have exhibited exciting potential as chemotherapy agents.
HNPs were fabricated and characterised using PCS, TEM, MRI, SQUID and
zeta potential measurement. Drug conjugation and release was quantiﬁed
using reverse phase HPLC. Cellular response and cytotoxicity assays were
carried out using trypan blue exclusion, MTT assay and atomic force
microscopy.
Results and Discussion: In our studies, we designed hybrid nanoparticles
(50 nm) capable of drug loading onto their surface (3:1:0.25, Drug:Fe:Au).
By exploiting the gold surface-to-drug interaction of a range of novel
Bisnaphtalamido based agents a system with heat triggered drug release was
produced. In vitro studies of these formulations showed the novel formulations
possess a 10-fold lower IC50 value when compared with the free drug after
only 24 h. These cytotoxicity studies combined with cellular uptake studies
showed the formulations to be signiﬁcantly more effective compared with
gemcitabine. In vivo trials have commenced to further elucidate their viability
for use as theranostics.
Conclusion: These data highlight the potential of HNPs as dual imaging
agents and contrast agents for pancreatic cancer therapy.
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